ASH , Lithuania , Albania Share this item Tom Eyckmans, MD, PhD from the Ziekenhuis Netwerk Antwerp, Antwerp, Belgium is commenting on his ASH 2019 Highlights in Sickle Cell Disease
Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3) Moshe Mittelman, MD, PhD from the Tel Aviv University, Tel Aviv, Israel is commenting on the abstract: Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)Blood (2019) 134 (Supplement_1): 3740.https://doi.org/10.1182/blood-2019-130309 ASH , Latvia , Lithuania , Estonia , Albania 00:07:06
ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania 00:03:29
EHA 2019 Srdan Verstovsek, MD, PhD - educational session MPN Srdan Verstovsek, MD, PhD from the MD Anderson Center, Houston, USA is commenting on the educational session on MPN, which took place during EHA 2019 in Amsterdam EHA , Countries , Latvia , Lithuania , Estonia , Albania 00:05:41
ASCO 2019 Dr. Susan Dent Dr. Susan Dent from the Duke Cancer Institute, North Carolina, VS is commenting on Reference: DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041) ASCO , Latvia , Lithuania , Estonia , Albania , Slovenia 00:05:01
ASCO 2019 Prof. Dirk Schadendorf, MD Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582) ASCO , Latvia , Lithuania , Estonia , Hungary , Albania 00:10:57
ESMO 2019 Highlights on melanoma presented at ESMO 2019 Philippe Saiag, MD, PhD and Prof. Jean Jacques Grob, MD are sharing their personal hightlights on melanoma from ESMO 2019 ESMO , Latvia , Lithuania , Estonia , Hungary , Albania 00:02:10
